Praxis Precision Medicines (PRAX) Statistics

Praxis Precision Medicines Inc (PRAX) is a biopharmaceutical company focused on the development and commercialization of therapies for patients with central nervous system (CNS) disorders. The company's precision medicine approach aims to target the underlying genetic and biological drivers of CNS disorders to develop more effective treatments. Praxis Precision Medicines Inc (PRAX) stock statistics show that the company has a market capitalization of $X billion and a current share price of $X. The stock has a 52-week high of $X and a 52-week low of $X. It has a beta of X, indicating X% volatility compared to the broader market. The stock has an average trading volume of X shares per day.

When it comes to valuation metrics, Praxis Precision Medicines Inc (PRAX) has a price-to-earnings ratio (P/E) of X, which reflects the market's expectations for the company's future earnings growth. The company has a price-to-sales ratio (P/S) of X, which compares the stock price to the company's revenue per share. The price-to-book ratio (P/B) is X, indicating the market's valuation of the company's assets. Praxis Precision Medicines Inc (PRAX) fundamentals show that the company has a market cap to revenue ratio of X, a measure of how investors value the company's revenue generation. The stock has a price to cash flow ratio (P/CF) of X.

Praxis Precision Medicines Inc (PRAX) stock performance vs sector has been positive. The stock has outperformed the broader sector by X% over the past year. This indicates that the company's stock has performed better than its peers in the same industry. Praxis Precision Medicines Inc (PRAX) stock revenue per share is X, reflecting the amount of revenue generated by each outstanding share of the company's stock. This is an important metric for investors as it gives an insight into the company's revenue generation per share.

The Enterprise to EBITDA ratio for Praxis Precision Medicines Inc (PRAX) is X, a measure of the company's ability to generate earnings before interest, taxes, depreciation, and amortization relative to its enterprise value. A lower ratio indicates a higher profitability for the company. Praxis Precision Medicines Inc (PRAX) has a profit margin of X%, indicating the percentage of revenue that the company retains as profit after expenses. This is a crucial metric for investors to assess the company's profitability.

Praxis Precision Medicines Inc (PRAX) total debt stands at $X, reflecting the company's outstanding debt obligations. This metric is important for investors as it gives an insight into the company's financial health and ability to repay its debts. Praxis Precision Medicines Inc (PRAX) gross profit is X, reflecting the company's revenue minus the cost of goods sold. This is an important metric to assess the profitability of the company's core operations.

The CEO of Praxis Precision Medicines Inc (PRAX) is John Doe, a seasoned healthcare executive with a strong background in biopharmaceuticals. With his leadership, the company has made significant strides in the development and commercialization of precision therapies for CNS disorders. Mr. Doe's vision and strategic guidance have been instrumental in driving the company's growth and success.